ArticleKidney medicine2026
Perinephric Myxoid Pseudotumor of Fat: Case Series, Systematic Review of the Literature, Clinical Classification, and Treatment Implications.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perinephric myxoid pseudotumor of fat (PMPF) is a rare and highly heterogeneous disease consisting of mature fat, myxoid stroma with spindled or stellate stromal cells histologically. Here, we present 2 cases of PMPF occurring in an allograft and a native kidney, and a systematic review that included 120 previously reported cases was subsequently conducted. Notably, 89% of PMPF cases with documented medical history had comorbidities. The most common comorbidities were urologic neoplasm (45%), chronic kidney disease (23%), allograft kidney (16%), and urinary tract obstruction (5%). We propose a classification of PMPF based on comorbidities and discovered that patients with concomitant urologic neoplasm or obstruction tended to have significantly smaller tumors, and active surveillance of PMPF after treating the primary disease might be an appropriate approach. In contrast, for patients with kidney transplants, chronic kidney disease, or no identifiable primary disease, the tumors were generally larger; therefore, surgical intervention should be considered. Regardless of the classification method used, for tumors exhibiting a slow growth rate, active surveillance should be considered. Our findings aimed to facilitate more accurate differential diagnosis and optimize treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.